Notícias

ISRG lifts margins despite tariffs, using scale, cost cuts and da Vinci 5 adoption to offset inflation as 2026 cost pressures build.

Over the long term, the IHI ETF looks like a good turnaround story.

Medtronic wants a bite of the robotics-assisted surgery market, which could swell to over $63 billion over the next decade.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

If you are wondering whether Intuitive Surgical at around US$418.82 is starting to look attractively priced or still expensive, it helps to break the story into what the stock has done recently and how that lines up with its fundamentals. The share price is down 1.1% over the past week, 7.2% over the past month, and 25.5% year to date, although it is still up 34.7% over three years and 46.2% over five years. These mixed returns sit against an ongoing stream of interest in robotic assisted...

Intuitive Surgical (ISRG) is back in focus after promoting Taylor Patton to Chief Commercial and Marketing Officer. This leadership shift puts commercial execution, global scaling, and its surgical data and AI ambitions under the spotlight for investors. See our latest analysis for Intuitive Surgical. The stock has fallen 25.5% year to date on a share price basis and is down 25.0% over the past year on a total shareholder return basis, signaling fading momentum despite a 46.3% total...

These stocks are down more than 10% this year, and now could be a great time to buy them for the long haul.

The robotic-surgery leader has lost nearly a third of its value since January. Here's what's weighing on the stock.

Securing 510(k) authorization would position Medtronic to compete with Intuitive in major robotic surgery markets.

Although Becton, Dickinson and Company has underperformed its sector peers recently, analysts remain moderately optimistic about the stock’s prospects.

Intuitive Surgical, Inc. (ISRG) reached $407.29 at the closing of the latest trading day, reflecting a +1.24% change compared to its last close.

Shares of Medtronic jumped 5% Wednesday after the medical-device maker reported better-than-expected quarterly results, helped by strong sales of devices used in heart procedures. The company also said it applied for U.

Intuitive Surgical falls 11% in a month despite strong revenues, procedure growth and da Vinci 5 adoption, raising questions about a potential rebound.

The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts’ estimates.

Medtronic stock jumped Wednesday after the medical products giant said it requested new clearances for its robotic surgery system.

Intuitive Surgical is building an AI-driven surgical ecosystem, using da Vinci 5 data and connected workflows to deepen its robotic surgery moat.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Don't wait too long to buy the dip on these stocks.

Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Despite recent underperformance relative to the healthcare sector, analysts remain fairly bullish on Intuitive Surgical's long-term fundamentals and growth potential.

This highly focused healthcare company has seen its shares fall 30% in 2026 despite still strong business growth.

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the 10 Best Debt-Free S&P 500 Stocks to Buy Now. On May 27, 2026, Goldman Sachs lowered the firm’s price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $558 from $621 and maintained a Buy rating on the shares. Goldman Sachs said MedTech has gone through one of its […]

In late May 2026, Intuitive Surgical announced that Global Senior Vice President of its endoluminal business Taylor Patton will become Chief Commercial and Marketing Officer from July 1, while Henry Charlton transitions to Senior Vice President of Global Business Operations. This leadership shift pairs Patton’s experience across the da Vinci, Ion, and digital platforms with Charlton’s operational focus, aiming to strengthen Intuitive’s ability to scale robotic-assisted and minimally invasive...

Intuitive Surgical's stock is in the middle of a deep drawdown, which is actually pretty common for this stock.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

Jensen Huang keeps quoting a $40 trillion humanoid robot TAM, and the market is rewarding every concept video and 2030 roadmap that mentions the word robot. I have been studying physical AI deployments for the better part of two years, and here is what I keep coming back to: the names that survive the inevitable ... 5 Stocks With Real Revenue From Physical AI Today (Not 2030 Promises)

Boston Scientific (BSX) previously commanded a premium valuation based on its transition toward a high-margin cardiovascular powerhouse, driven by its FARAPULSE Pulsed Field Ablation (PFA) system and WATCHMAN cardiac implant. In Q1 2026, the cardiovascular segment posted a strong 13.5% reported growth. However, intense competition from Medtronic (MDT) and Johnson & Johnson (JNJ) has challenged this hyper-growth thesis. Johnson & Johnson's Varipulse system integrates directly into the dominant CA

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best medical technology stocks to buy right now. On May 21, Intuitive Surgical, Inc. (NASDAQ:ISRG) announced a major round of updates to its da Vinci 5 robotic surgical system, including extended instrument use capabilities. The company said more than 100 improvements will roll out to US customers […]

Intuitive Surgical (ISRG) is well positioned to outperform the market, as it exhibits above-average growth in financials.

ISRG is widening its robotic surgery lead with faster growth, rising procedures and a recurring revenue model as Medtronic builds Hugo.